Brief: I-Mab Transitions To NovaBridge Biosciences With Trading Effective October 30, 2025
29/10/2025 14:32
Oct 29 (Reuters) - I-Mab IMAB.O: I-MAB (NASDAQ: IMAB) TRANSITIONS TO NOVABRIDGE BIOSCIENCES (NASDAQ: NBP) WITH TRADING EFFECTIVE OCTOBER 30, 2025 NEW BRAND AND LOGO TO REFLECT STRATEGIC TRANSFORMATION TO A GLOBAL BIOTECH PLATFORM Source text: ID:nGNX22YXZV Further company coverage: IMAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview